- FLU AND IBD -
Influenza is a viral infectious disease caused by some influenza viruses. These viruses are
characterized by some surface proteins (called H and N) that distinguish the different kinds of agents.
Common seasonal influenza is caused by the type A virus, with two subtypes, H1N1 and H3N2 that
affect million of people every year. Recently, a new H1N1 virus has widespread in all continents
determining a new pandemic influenza (known as swine flu), that resulted more contagious than
seasonal flu. The WHO is monitoring the spreading of this new kind of illness and morbidity and
mortality rate. Even though more contagious, mortality rate is rather low (about 0,3% in Europe),
especially concerning people with severe comorbidities.
Both seasonal flu and “swine” flu can have a mild severity up to lead to death. They usually
cause asthenia, fever, cough, muscular and joints pain, and are often self-limiting. Some patients with
cardiac or respiratory diseases may have complications of their diseases due to influenza. The best
way to prevent the infection is to vaccine against the infection as well as behaving according to
A new vaccine for this new kind of influenza has been quickly developed and tested, resulting
to be efficacious and safe as well as the seasonal flu vaccine. It is thus recommended to vaccine as
more people as possible, in order to stop the diffusion of this new virus and to protect high risk
Patients with IBD are strongly recommended to vaccine themselves against several infectious agents,
especially when under immunosuppresant therapy, that is steroids, azathioprine and 6-
mercaptopurine, cyclosporine, methotrexate and anti TNF-a agents. The medical immunosuppression
increases the risk to get infections, then the patient should carefully follow everyday preventive
actions. The possibility to vaccinate should be discussed carefully together with the gastroenterologist,
considering individual risks and benefits. It has been reported that patients on immunosuppression
may not develop an adequate immune response against the vaccine, then the eventuality to boost the
vaccine effects should be considered (dosing immunoglobulines, following preventive hygienic rules,
Considering the WHO recommendations, EFCCA suggests to all patients:
Vaccinate yourself. The EFCCA recommends a yearly seasonal flu vaccine. Because seasonal flu
vaccine will not protect against H1N1 2009, it is appropriate to vaccinate against both viruses. The
optimum time to get vaccinated against the flu is from late October to mid-November. A flu shot takes
one to two weeks to be effective. You are not protected from the flu until the flu shot takes effect. For
“swine” influenza you should be vaccinated twice, again after 3 weeks after first shot. All three
vaccines which are approved by EMEA are acceptable for IBD patients and those who take any
immunosuppressive drug. If you are on anti-TNF therapy you should got influenza vaccine shot at the
middle of period between two anti-TNF therapy
Take everyday preventive actions: Cover your nose and mouth with a tissue when you cough
or sneeze; wash hands frequently with soap and water (take 20 seconds at least); avoid touching
your eyes, nose, or mouth; avoid close contact with sick people as much as possible.
Take flu antiviral drugs if recommended by your doctor. If you get seasonal or “swine” H1N1
flu, antiviral drugs can treat the flu. Antiviral drugs are medicines (pills, liquid or an inhaled powder)
that keep the viruses from reproducing in your body. Please, remember that antiviral drugs are
effective in the earliest stage of the disease and that must be taken only after medical prescription.
http://www.emea.europa.eu/influenza/vaccines/home.htm
http://www.ccfa.org/frameviewer/?url=/media/pdf/FactSheets/flufinal.pdf
http://www.ccfa.org/frameviewer/?url=/media/pdf/FactSheets/flufinal.pdf
edited by: Prof. Silvio Danese – Humanitas Clinical Institute Milan In collaboration with Dr. Dusan Baraga – EFCCA Director
Effect of common antimicrobial agents on the growth and metabolism of Megasphaera elsdenii NCIMB 41125, a lactate utilising probiotic for ruminants. By J. APAJALAHTI1, P.H. HENNING2, C.H. HORN2, S. ALAJA1, and A. KETTUNEN1. 1Alimetrics Ltd, Koskelontie 19B, FI-02920, Espoo, Finland, 2KK Animal Nutrition, PO Box 10520, Centurion 0046, South Africa Acute lactic acidosis is a rumen f
Publication : Yes, and… Publication date : What’s going on? – Communicating in times of change All organisations should have a communication strategy but during times of change it becomes vital. There are several reasons why this is so important: Change or the prospect of change affects people in different ways, but to many it can be profou